Pharmacovigilance, or PV, is the process of continuously monitoring pharmaceuticals once they are put on the market in order to evaluate and enhance their safety profile. Increasing the number of adverse drug reactions (ADRs) that are spontaneously reported is the primary goal in order to collect a wide range of data. The World Health Organization (WHO) defined pharmacovigilance as the science and set of procedures concerning the identification, assessment, comprehension, and rejection of negative effects or problems associated with various drugs in nursing. A clinical test may involve an analysis study involving human subjects in order to address particular health questions. Carefully carried out clinical trials are the fastest and safest methods because they help individuals receive treatments that work and because they improve health. Pharmacovigilance, which provides information on the negative effects that the drug-using population typically experiences, is acknowledged to be essential to the sensible use of pharmaceuticals. Adverse drug reactions (ADRs) are becoming more and more common, and various methods, including scientific and administrative research, in-depth observation, impromptu reporting, and information studies, are being developed with the goal of enhancing pharmacovigilance. Because assessment procedures contain some subjective judgements, integrator reliability is frequently low. In summary, there is presently no well recognized mechanism for assessing casualties from ADRs.